Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine

Vreman, Sandra; McCaffrey, Joanne; Graaf, Ditta J. Popma-De; Nauwynck, Hans; Savelkoul, H.F.J.; Moore, Anne; Rebel, Johanna M.J.; Stockhofe-Zurwieden, Norbert

doi:10.1016/j.vetimm.2019.04.008

Cited by 23 publications

(20 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous novel immunization strategies, including multicomponent (e.g., Figure 3) and temporal release vaccination, have been devised with MNAs to further improve the efficacy, longevity, breadth, and protection capacity of MNA- administered vaccines. To this end, several different immunestimulants/adjuvants, such as imiquimod (TLR7/8 agonist), c-di-GMP (STING pathway agonist), polyinosinic:polycytidylic acid (poly(I:C), a TLR3 agonist), platycodin (saponin adjuvant), monophosphoryl lipid A (TLR4 agonist), Quil-A (saponin adjuvant), resiquimod (TLR7/8 agonist), glucopyranosyl lipid adjuvant (GLA, TLR4 ligand), or CpG oligonucleotides (TLR9 ligand), have been used with the same MNAs to enhance the immune responses to the antigen delivered to the skin [214][215][216][217][218][219][220][221][222][223][224]. A few small-molecule adjuvants, such as imiquimod, could also be topically applied to the skin prior to MNA delivery of antigens or could be formulated with STAR particles and SNAs for enhanced topical vaccination.…”

Section: Microneedle Arraysmentioning

confidence: 99%

Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases

Korkmaz

Balmert

Carey

et al. 2020

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Infectious pathogens are global disrupters. Progress in biomedical science and technology has expanded the public health arsenal against infectious diseases. Specifically, vaccination has reduced the burden of infectious pathogens. Engineering systemic immunity by harnessing the cutaneous immune network has been particularly attractive since the skin is an easily accessible immuneresponsive organ. Recent advances in skin-targeted drug delivery strategies have enabled safe, patientfriendly, and controlled deployment of vaccines to cutaneous microenvironments for inducing longlived pathogen-specific immunity to mitigate infectious diseases, including COVID-19.Areas covered: This review briefly discusses the basics of cutaneous immunomodulation and provides a concise overview of emerging skin-targeted drug delivery systems that enable safe, minimally invasive, and effective intracutaneous administration of vaccines for engineering systemic immune responses to combat infectious diseases. Expert opinion: In-situ engineering of the cutaneous microenvironment using emerging skin-targeted vaccine delivery systems offers remarkable potential to develop diverse immunization strategies against pathogens. Mechanistic studies with standard correlates of vaccine efficacy will be important to compare innovative intracutaneous drug delivery strategies to each other and to existing clinical approaches. Cost-benefit analyses will be necessary for developing effective commercialization strategies. Significant involvement of industry and/or government will be imperative for successfully bringing novel skin-targeted vaccine delivery methods to market for their widespread use.

show abstract

Section: Microneedle Arraysmentioning

confidence: 99%

Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases

Korkmaz

Balmert

Carey

et al. 2020

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…In order to enhance the immune efficacy in vivo of recombinant protein JointS, it is necessary to select an effective and safe adjuvant to stimulate the immune response of the host. Most TLR-related agonists are potential candidates for swine vaccine adjuvants due to their ability to induce a pro-inflammatory cytokine response and immune cell activation [37][38][39]. However, there is no evidence that TLR-related agonists performed as an adjuvant combined with inactivated or subunit vaccines to prevent S. suis infections in pigs.…”

Section: Discussionmentioning

confidence: 99%

TLR4 Agonist Combined with Trivalent Protein JointS of Streptococcus suis Provides Immunological Protection in Animals

et al. 2021

View full text Add to dashboard Cite

Streptococcus suis (S. suis) serotype 2 (SS2) is the causative agent of swine streptococcosis and can cause severe diseases in both pigs and humans. Although the traditional inactive vaccine can protect pigs from SS2 infection, novel vaccine candidates are needed to overcome its shortcomings. Three infection-associated proteins in S. suis—muramidase-released protein (MRP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and DLD, a novel putative dihydrolipoamide dehydrogenase—have been previously identified by immunoproteomic assays. In this study, the effective immune protection of the recombinant trivalent protein GAPDH-MRP-DLD (JointS) against SS2, SS7, and SS9 was determined in zebrafish. To improve the immune efficacy of JointS, monophosphoryl lipid A (MPLA) as a TLR4 agonist adjuvant, which induces a strong innate immune response in the immune cells of mice and pigs, was combined with JointS to immunize the mice. The results showed that immunized mice could induce the production of a high titer of anti-S. suis antibodies; as a result, 100% of mice survived after SS2 infection. Furthermore, JointS provides good protection against virulent SS2 strain infections in piglets. Given the above, there is potential to develop JointS as a novel subunit vaccine for piglets to prevent infection by SS2 and other S. suis serotypes.

show abstract

“…Since the licensed VZV vaccine took the first step in clinical herpes virus immunization, it has brought home the lesson that appropriate adjuvants used in vaccine formulation can greatly enhance the immunization efficacy. Additionally, the rising application of specific toll-like receptor (TLR) agonists (134)(135)(136) provides additional alternatives in the selection of adjuvants to achieve specific immunization responses.…”

Section: Adjuvants For Vaccine Formulationmentioning

confidence: 99%

The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development

et al. 2021

View full text Add to dashboard Cite

Epstein–Barr virus (EBV) is a human herpesvirus that is common among the global population, causing an enormous disease burden. EBV can directly cause infectious mononucleosis and is also associated with various malignancies and autoimmune diseases. In order to prevent primary infection and subsequent chronic disease, efforts have been made to develop a prophylactic vaccine against EBV in recent years, but there is still no vaccine in clinical use. The outbreak of the COVID-19 pandemic and the global cooperation in vaccine development against SARS-CoV-2 provide insights for next-generation antiviral vaccine design and opportunities for developing an effective prophylactic EBV vaccine. With improvements in antigen selection, vaccine platforms, formulation and evaluation systems, novel vaccines against EBV are expected to elicit dual protection against infection of both B lymphocytes and epithelial cells. This would provide sustainable immunity against EBV-associated malignancies, finally enabling the control of worldwide EBV infection and management of EBV-associated diseases.

show abstract

Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine

Cited by 23 publications

References 68 publications

Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases

Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases

TLR4 Agonist Combined with Trivalent Protein JointS of Streptococcus suis Provides Immunological Protection in Animals

The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development

Contact Info

Product

Resources

About